The Evidence Based Rheumatology Podcast
A podcast for physicians focused on evidence-based medicine in rheumatology. Each episode critiques and applies a recent paper from the medical literature to clinical practice. The show aims to help clinicians interpret research findings and incorporate them into patient care. It is hosted by a rheumatologist and covers topics relevant to the field.
Episodes
E138: Dapirolizumab for SLE (PHOENYCS-GO)
A new therapy for SLE! This one is a CD40-CD40L blocker, which has some nice new-things to inhibit. The study itself was a qualified success and the podcast got a bit more rant-y than it should have been, but hopefully you get a kick out of it.
Paper: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00691-4/fulltext
E137: Obexelimab in IgG4-RD (INDIGO)
Another day, another B cell drug. This one adds an interesting option for IgG4-RD, offering a "maybe less efficacious maybe less toxic" pathway. I could see folks being excited for this, especially in a disease where non-scary-manifestations are relatively common.
Also, check out boardsbank.com!
Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2601337
E136: Secukinumab in PMR (REPLENISH)
Big trial this week in the NEJM investigating the IL17 inhibitor secukinumab in PMR. Well worth a read, I would bet on FDA approval in the near future. Some interesting tidbits and of course a weird safety thing we now have to grapple with.
Be sure to go to boardsbank.com! Free rheumatology board review, >1000 questions!
Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2602567
E135: IL17 and a GLP1?
Really interesting study this week comparing the IL17 inhibitor ixekizumab WITH the GLP1 inhibitor tirzepatide to ixekizumab alone. Raises some interesting questions about what worked here and whether or not it matters how it worked.
Paper: https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.70134
Newsletter: http://autoimmunedevreport.com/
E134: Brepocitinib in Dermatomyositis (VALOR)
Great trial this week looking at brepocitinib in dermatomyositis. Looks like a winner, expect it will be approved. Where it fits in our approach to IIM is an open question, but nice to have another option.
Study: https://www.nejm.org/doi/10.1056/NEJMoa2503531
JC Companion: https://autoimmunedevreport.substack.com/
E133: Obinutuzumab for SLE (ALLEGORY)
Good RCT this week, investigating the CD20 B cell inhibitor obinutuzumab for SLE. Sign up for my newsletter if you would like to have a read-along companion piece!
Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2516150
Landing Page: https://ebrheum.com/
Substack: https://autoimmunedevreport.substack.com/
E132: Romosozumab vs teriparatide for osteoproosis (STRUCTURE)
Quick podcast this week about a nifty head to head study that I had previously missed. Worth reading if - like me - you're still trying to figure out how the heck to manage osteoporosis.
Paper: https://pubmed.ncbi.nlm.nih.gov/28755782/
E131: A Sham-Controlled Sham of a Trial: RESET-RA
Today I cover the recent publication of the RESET-RA study, which evaluated vagal nerve stimulation to treat rheumatoid arthritis. Have a listen in full, but let me be clear upfront: I do not think this works and will not be referring any patients to receive it. This will forever be my pivotal example of the effect of unblinding, but would love to hear if you think different!
Paper: https://www
E130: Telitacicept for SLE
Surprisingly (unbelievably?) impressive RCT evaluating the Blys/APRIL inhibitor "telitacicept" for patients with SLE (mixed SLE and SLE-LN). Very curious to see where the FDA goes with this one.
Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2414719
E129: Long Term Routine Laboratory Monitoring in RA
Ever wonder how often you really need to check "monitoring" labs? If so then this is the podcast for you! Bryant England mentioned this during his excellent Year in Review session at ACR Convergence 2025. I've been meaning to cover it and finally got around to doing so. Have a listen and share with friends!
Paper: https://pubmed.ncbi.nlm.nih.gov/40854212/
E128: Nerandomilast for Autoimmune ILD (FIBRONEER-ILD)
Covering a very interesting study this week, which investiaged the PDE4B inhibitor nerandomilast for patients with progressive pulmonary fibrosis (specifically including 325 patients with autoimmune ILD). Would have been yet another ho hum trial if not for the big reveal... have a listen to find out!
Article: https://www.nejm.org/doi/full/10.1056/NEJMoa2503643
E127: TNFs and All That CHF
Another episode looking into safety this week! Tackling that pesky issue of TNFs and CHF. Be sure to subscribe to my newsletter and check out the papers below!
Newsletter: https://sprw.io/stt-ee87b4
ATTACH: https://pubmed.ncbi.nlm.nih.gov/12796126/
RENEWAL: https://www.ahajournals.org/doi/10.1161/01.cir.0000124490.27666.b2
Observational Studies: https://pubmed.ncbi.nlm.nih.gov/23155221/
E126: Risk Signals, JAKs, and SELECTIVE-ity
Covering an interesting but ultimately disappointing post hoc study of multiple upadacitinib trials in RA. Initially some hope for clarity in the "Do JAKs cause all the badness?" questions, but ultimately landing me about where I have been since ORAL-SURVEILLANCE was published
Paper: https://www.sciencedirect.com/science/article/pii/S0003496724423091
E125: Adrenal Insufficiency after Stopping Prednisone
Interesting read this week - I cover a nifty little paper that presented data about adrenal insufficiency after stopping prednisolone, published in JAMA Open in March 2025.
Open Access Journal Here: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2831668
e124: MTX vs Pred for Pulmonary Sarcoidosis: PREDMETH Study
Interesting NEJM trial this week comparing methotrexate to prednisone for pulmonary sarcoidosis.
Paper available here: https://www.nejm.org/doi/full/10.1056/NEJMoa2501443
E123: Upadacitinib for Giant Cell Arteritis: SELECT-GCA
Podcast this week about the recently published SELECT-GCA study, which evaluated the use of the janus kinase inhibitor upadacitinib (Rinvoq) for patients with new and relapsing GCA. Successful trial and an interesting topic. Paper itself here: https://www.nejm.org/doi/full/10.1056/NEJMoa2413449
E122: Guidelines for Maybe Diagnosing HLH
This week I cover another of my newsletters, though I mostly use it as a skeleton to riff on a common (and challenging) issue for rheumatology consultants; diagnosing HLH. Check out the guidelines themselves here and have a listen to the podcast!
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00273-4/fulltext
E121: Obinutuzumab in SLE-LN
Another day, another b cell podcast. Seems to be all the rage! This week I discuss the recently published NEJM trial of the anti CD20 agent obinutuzumab in lupus nephritis. Worth a read and listen, paper can be found here: https://www.nejm.org/doi/full/10.1056/NEJMoa2410965
E120: Real Life Use of PEXIVAS-Low
What do you do when observational data and RCTs conflict? This week I'm covering the "real world PEXIVAS" study that was done by the French Vasculitis Study Group. Great read, interesting issues, have a listen and be sure to share with friends!
E119: Teclistamab for Rheumatology Writ Large
One of my rare case-report podcasts, a topic that I typically avoid. The craze about CAR-T has also made me a little crazy, though, so I wanted to share what I think may be the ultimate destination for "more B cell depletion than rituximab" strategies.
Article: https://www.nejm.org/doi/full/10.1056/NEJMc2407150
E118: The emerging risk of overdiagnosis in RA and PMR
Podcast this week about overdiagnosis! Currently one of my favorite topics and something that I think will be an emerging issue in our field. We recently published a Viewpoint in Lancet Rheumatology (https://pubmed.ncbi.nlm.nih.gov/39341221/) addressing this issue. I'm going to read from it and after that will be giving a few final (spicy) thoughts on the topic. Hope you find it worthwhile! s
E117: Inebilizumab for IgG4-RD (MITIGATE)
New RCT in a new disease with a new drug! But is it as shiny as one would hope? Interesting discussion today about what a trial means, how it will affect practice, and how we could do better as a field. Happy holidays everyone!
E116: A New Paradigm for PMR
Reading one of my recent newsletters this week, this one about PMR tapers. Be sure to subscribe at ebrheum.com if you want access to the visuals and upcoming editions!
E115: Benralizumab for EGPA - the MANDARA Study
Quick rundown of an important rheumatology RCT this week, discussing the IL-5 inhibitor benralizumab for the treatment of relapsing/refractory EGPA.
MANDARA Study: https://www.nejm.org/doi/full/10.1056/NEJMoa2311155
E114: Target Trials and STAR-RA with Rishi Desai
Important methodology podcast this week, covering a lot of ground with expert epidemiologist Rishi Desai. Really enjoyed our conversation and glad to be publishing today!
**House Keeping Note: we actually recorded this ~15 months ago but I somehow lost the audio... which somehow re-appeared! #technology
STAR-RA: https://pubmed.ncbi.nlm.nih.gov/35027405/
E113: CAR-T is Coming to Rheumatology
Exciting podcast this week about the upcoming / impending use of CAR-T in rheumatology. Highly recommend rheumatologists learn about this now; it's going to be a big thing for many years to come. In a future episode I will lay out my case for skepticism, but for now I think a good run down of the first big published series will be enough!
NEJM CAR-T Case Series: https://www.nejm.org/doi/full/10
E112: Gabapentin is Trash
This week's podcast will be a quick read of one of my newsletters. The title basically speaks for itself! Find the newsletter and my other work at ebrheum.com
E111: PEXIVAS Subsets with Mike Walsh & Mats Junek
At ACR23 I had a twitter-disagreement about steroid tapers from PEXIVAS with Mike Walsh, the lead author on the PEXIVAS trial. He kindly agreed to join me for a moderated discussion. Loved hearing his perspective and have to admit he pulled me closer to his practice... but not all the way there. Longer podcast than usual but I prefer to release audio uncut and this took as long as it needed! Hopin
E110: Rheum4Debate - Screening for RA-ILD with Joshua Solomon and Scott Matson
Rheum4Debate is back!
In this episode I moderated a debate between two pulmonologists about RA-ILD. As a reminder, Rheum4Debate is an Oxford-style debate show, where two debators disagree over a motion during 3 rounds of discussion. The motion for todays show was:
“Asymptomatic patients with rheumatoid arthritis and high risk features for interstitial lung disease should be screened using pulmona
E109: Abatacept for Pre-RA - the ARIAA Study
Nice study this week on an important topic. Can we prevent the development of rheumatoid arthritis by initiating DMARDs during a preclinical phase? Lots to discuss: what does it mean to be "pre-clinical?" How does this fit with other studies of this nature?
Check it out! https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02650-8/fulltext
E108: Myositis Guidelines for Cancer Screening w/Alexander Oldroyd
Informative podcast this week with Dr. Alexander Oldroyd, the first author of the recently published "International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening." The article itself appeared in Nature Reviews Rheumatology and provides what I think is a very useful framework for approaching this issue.
Article: https://www.nature.com/articles/s41584-023-01045-w
E107: Fragility of SLE Randomized Controlled Trials
Quick methodology episode this week discussing the concept of "fragility" in randomized controlled trials of lupus. Really enjoyed discussing this paper and was grateful to have been a part of it. Get the text here: https://lupus.bmj.com/content/lupusscimed/11/1/e001068.full.pdf
E106: GCA/PMR with Bhaskar Dasgupta
Today I'm taking another twitter discussion into the podcast realm! Dr. Bhaskar Dasgupta has published hundreds of papers about polymyalgia rheumatica and giant cell arteritis, including a recent publication in Nature Reviews: Rheumatology that piqued my interest (https://www.nature.com/articles/s41584-023-00976-8).
In this podcast we discuss screening for GCA among patients with PMR, what it m
E105: Autoimmunity Post COVID-19?
Interesting topic and interesting paper this year, including discussion of observational biases, positive and negative controls, and interpreting data as it comes.
Paper: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2810259
E104: Sarilumab for PMR - The SAPHYR Study
Important trial on the podcast this week! I take a deep dive into the recently published SAPHYR study, which evaluated the use of the IL6 inhibitor sarilumab for patients with PMR. A few aggravating quibbles but overall a very useful trial and an important step forward for patients with PMR.
Article: https://www.nejm.org/doi/full/10.1056/NEJMoa2303452
E103: Len Calabrese on Monoclonal Antibodies for COVID-19
This week I took a twitter disagreement from the impersonal world of twitter to the podcast world of a back and forth conversation. Really enjoyed talking to Dr. Len Calabrese about monoclonal antibodies, FDA regulatory pathways, and life in general.
E102: Unintentional Unblinding in Rheumatic Disease Trials
Excited to share an editorial that I wrote along with Cody Bruggemeyer and Desh Nepal, two trainees with me at the Medical College of Wisconsin. We discussed what I believe to be a pervasive (but seldom discussed) issue in rheumatology RCTs: unblinding. I suspect many of our studies suffer from this. Have a listen!
E101: Pred v Colchicine for CPPD: COLCHICORT
Happy to share the FIRST randomized trial in CPPD today. It's kind of a weird study but worth a quick discussion.
https://www.sciencedirect.com/science/article/pii/S2665991323001650
E100: ADVOCATE Health Related Quality of Life
This week I dive into the health related quality of life measures that were reported in the ADVOCATE study. I found them overall somewhat convincing and they have affected my practice. Have a listen and be sure to follow along. Find my work at ebrheum.com
E99: Hospital Problems
Quick episode this week from a recent Perspective piece I had published in the New England Journal. Have a listen or a read!
https://www.nejm.org/doi/full/10.1056/NEJMp2304828
E98: Key Opinion Leaders & ILD Guidelines
Podcast this week discussing key opinion leaders (KOLs) and pharmaceutical companies. Please subscribe to my newsletter (ebrheum.com) and be sure to share the podcast with friends!
E97: Does allopurinol reduce CVD? The ALLHEART Study
Nice quick RCT rundown this week, covering the ALLHEART study, a pragmatic RCT of urate lowering therapy to reduce cardiovascular disease. Quick listen for a useful teaching point!
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01657-9/fulltext
E96: Long COVID - Where to After Norway?
Today I cover the recently published long-COVID study from Norway. It's a great paper that challenges much of the prevailing wisdom. I think there are some interesting limitations, but anyone who sees post COVID patients (aka all of us) would do well to read it. Or have a listen here!
PDF: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2802893
E95: Rituximab or Cyclophosphamide in ANCA Vasculitis
Fun study this week from JAMA Network Open and the French Vasculitis Study Group. They used a target trial emulation (one of my favorites) to ask whether RTX > CYC in AAV (another one of my favorites). I tried to use this to compare between observational and randomized data.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2799018
E94: Steroids and Psoriasis Flares
This week I hope to debunk one of rheumatology's "paradoxes." We love to talk about these and subject our fellows to memorizing them for the boards. We often use them to guide clinical practice, but I suspect that many "paradoxes" are actually the result of shoddy epidemiology. Todays' paper from JAMA dermatology covers one that I have heard frequently, which is that steroids cause psoriasis flare
E93: Azathioprine is the Worst
Today I'll be reading one of my recent newsletters! It's kind of a fun run-down of my anti-azathioprine stance. As I say in the piece, some patients may benefit from azathioprine and I am not saying it is an entirely useless drug or that nobody should ever prescribe it. Rather, I am just saying that it is likely the worst option for nearly every indication for which it could be prescribed.
Please
E92: Are muscle symptoms from statins imaginary?
Today I review a recent large meta analysis of randomized controlled trials of statin use. Super interesting findings that have changed my clinical practice. Check out the paper here and listen to the episode!
Paper: https://www.thelancet.com/article/S0140-6736(22)01545-8/fulltext
"Internet driven cult" editorial: https://pubmed.ncbi.nlm.nih.gov/28738422/
E91: Clinical Innovation in Rheumatology: Past, Present, and Future
Change of pace today! I interviewed Jason Liebowitz and Phil Seo about their new book entitled "Clinical Innovation in Rheumatology: Past, Present, and Future." I thoroughly enjoyed the book and had a great time interviewing them about some of their "futuristic" topics. Grab the book (or better yet, have your division get some copies) at the link below and be sure to share the podcast with friends
E90: There Is No Diagnosis of Exclusion in Rheumatology
Quick episode this week to share an editorial I recently wrote with Jay Patel and Anisha Dua. We cover one of my least phrases in medicine, the "diagnosis of exclusion."
Hope you enjoy! Find the original paper here: https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keac278/6584804
E89: Vitamin D to Prevent Osteoporotic Fractures
Exciting (negative) results from a large RCT on the podcast this week as well as a (mini) rant about how we should be spending our time as rheumatologists and the false security of ineffective treatments.
Let me know what you think on twitter @ebhruem
https://www.nejm.org/doi/full/10.1056/NEJMoa2202106
E88: HCQ Dose Reductions and SLE Flares
Interesting case-crossover study today evaluating the association between HCQ dosing and risk of SLE flares. Super worth your time to read the paper or listen to this episode!
https://jamanetwork.com/journals/jama/article-abstract/2796634
E87: IVIG for Dermatomyositis
Podcast is back! This week I discuss a pivotal RCT in dermatomyositis. Check it out and be sure to subscribe to my newsletter at ebrheum.com!
E86: Target Trials and Causality in Rheumatology
Mixing it up again this week to discuss an editorial by Miguel Hernan and a systematic review of target trials in rheumatology. It's kind of a fun free-form stream of consciousness. Hope you enjoy! Links:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888052/
https://pubmed.ncbi.nlm.nih.gov/32381560/
E85: Challenging Wisely
Quick episode today. I wanted to share an editorial that was recently published in Rheumatology, where I and co-authors (Shannon Tai and Natalie Anumolu) discuss lessons from recent trials in AAV and SLE.
Link to editorial: https://pubmed.ncbi.nlm.nih.gov/35438142/
E84: The JAKapocalypse (AKA ORAL Surveillance)
After some delay, I finally get around to discussing ORAL-Surveillance, a post-marketing safety study of tofacitinib for rheumatoid arthritis. It's an incredibly important trial that will likely affect how all of us practice for the foreseeable future. Link to paper:
https://www.nejm.org/doi/full/10.1056/NEJMoa2109927
E83: Effectiveness of COVID-19 Vaccines
After a winter hiatus, the podcast is back! Today I wanted to dive into a 'hotbutton' issue - the question of whether (or not) COVID-19 vaccines "work" for patients with rheumatic diseases. My answer is an emphatic "yes," albeit with a few caveats. Here are the papers I discuss:
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(22)00034-0/fulltext
https://pubmed.ncbi.nlm.nih.gov/3
E82: LoVAS Trial for ANCA Vasculitis
Hello again! Snappy episode this week about the exciting LoVAS trial, which compared a reduced dose steroid taper for ANCA vasculitis. Be sure to drop by my website at ebrheum.com to subscribe to my newsletter!
E81: Vasculitis Guidelines E7: Takayasu Arteritis with Dr. Andy Abril
In this episode, I talk with Dr. Andy Abril, Chair at the Division of Rheumatology at the Mayo Clinic in Jacksonville Florida. Dr. Abril is one of the lead authors for the 2021 ACR Guidelines on Takayasu’s arteritis.
This project was done in partnership with the Vasculitis Foundation. To review the complete guidelines, visit
https://dev.vasculitisfoundation.org/2021-acr-vf-vasculitis-guidelines/
E80: Vasculitis Guidelines E6 - Polyarteritis Nodosa with Dr. Jason Springer
In this episode, I talk with Dr. Jason Springer, Co-Director of the Vanderbilt Vasculitis Center, about the guidelines for PAN He is one of the lead authors for the ACR/VF Guidelines for Polyarteritis Nodosa.
This project was done in partnership with the Vasculitis Foundation. To review the complete guidelines, visit
https://dev.vasculitisfoundation.org/2021-acr-vf-vasculitis-guidelines/ or vascu
E79: Vasculitis Guidelines E5 - GCA with Dr. Mehrdad Maz
On today's episode I discuss GCA with Dr. Mehrdad Maz. He is the Division Director of the Kansas University Allergy, Clinical Immunology and Rheumatology Section and served on the Steering Core Committee of the ACR-VF Vasculitis Treatment Guidelines. We cover a lot of great topics!
This project was done in partnership with the Vasculitis Foundation. To review the complete guidelines, visit
https:
E78: Vasculitis Guidelines #4 - EGPA with Dr. Phil Seo
In today's episode, I talk with Dr. Mehrdad Maz about the newly published guidelines for giant cell arteritis (GCA). Dr. Maz is the Division Director of the Kansas University Allergy, Clinical Immunology and Rheumatology Section. He serves on the Steering Core Committee of the ACR-VF Vasculitis Treatment Guidelines.
This project was done in partnership with the Vasculitis Foundation. To review t
E77: Vasculitis Guidelines #3 - ANCA Vasculitis with Dr. Sharon Chung
The guidelines have finally arrived! I'm kicking off the series today with a conversation about the ANCA vasculitis guidelines. My guest is Dr. Sharon Chung, the director of the UCSF Vasculitis Clinic and the lead investigator on the ACR/Guideline committee. She provided a LOT of great insights; have a listen and let us know what you think!
This project was done in partnership with the Vasculit
E76: Voclosporin for SLE Nephritis: The AURORA RCT
Hopping in this week to round out my thoughts on ADVOCATE (avacopan in AAV) and covering the recently published AURORA trial for SLE nephritis. Back to the Vasculitis Guidelines Podcast after as soon as they are released!
E75: Vasculitis Guidelines Episode 2: Overview with Sharon Chung
In this episode we'll be introducing the process by which the 2021 ACR/VF guidelines were produced. My guest is Dr. Sharon Chung. She's the director of the UCSF Vasculitis Clinic and the lead investigator on the guideline committee. Please follow along with future episodes - you can find me @ebrheum and the Vasculitis Foundation is at @vasculitisfound and their website vasculitisfoundation.org.
E74: Vasculitis Guidelines Episode 1 - Joyce Kullman
Welcome to the first episode of the Vasculitis Guidelines Podcast! In Episode 1, I interview Joyce Kullman, Executive Director of the Vasculitis Foundation, about collaborating with the ACR in updating these guidelines, and how patients with vasculitis will ultimately benefit from them. We discuss the complex process of updating these critical guidelines involve years of input from researchers, p
E73: Introducing the Vasculitis Guidelines Podcast
Quick update on a new series!
E72: Avacopan for ANCA Vasculitis
Steroid free remission! Or is it? This week I discuss a really exciting trial in ANCA vasculitis.
E71: MTX Discontinuation Post... Influenza Vaccination
I stole some time to tackle a pressing issue for rheumatologists - to hold or not to hold immunosuppression in patients who are receiving a COVID19 vaccination. We obviously don't have any data on this, but I have always loved this study on influenza vaccination. PDFs at ebrheum.com/twts and follow me on twitter @ebrheum!
E70: Rheum4Debate - HCQ Levels Should Be Monitored in Patients with SLE
We have a great show for you this week! Anisha Dua will be moderating a debate
between myself and Max Konig on this motion: "Hydroxychloroquine levels should be monitored in patients with SLE." I learned a ton and thoroughly enjoyed it. Be sure to vote on the post-debate twitter poll to decide the winner!
E69: Publication Trends in SRMAs and RCTs
This week I cover another of my meta-research projects, this one on systematic review and meta analysis (SRMA) growth as compared to randomized clinical trial (RCT) growth. Short and to the point - hope you enjoy! I highly recommend checking out the associated graphs - just take a quick peek at some point while listening. Find them on my twitter handle @ebrheum
E68: SELECT-CHOICE Upadacitinib vs Abatacept in RA
Active comparator trial! Always my favorite. Lots of fun topics in this one, including noninferiority trials, crafty endpoints, and PROs. Check it out and let me know what you think! @ebrheum
E67: Belimumab in Lupus Nephritis (BLISS-LN)
Another day, another lupus trial, another round of endpoint shenanigans. Why does that matter? How big is the benefit from belimumab in SLE nephritis? Will this save lives and prevent ESRD / RRT? I try to tackle these issues this week and (hopefully) avoid getting myself in trouble. Hope you enjoy the episode! Let me know what you think @ebrheum on twitter!
E66: MRI to Diagnose PMR
Great paper to discuss this week - one that may be too good to believe? I highly recommend checking out the pdf first (ebrheum.com/twts) - their graphics are wonderful and do a great job of conveying their message. Also, check out the "2-5-10" rule that I referenced! This is required reading for anyone who rotates with me - easily one of the most useful EBM papers I have ever read.
E65: Anifrolumab in SLE - A Reply
Quick podcast this week that expands on issues I discuss in Episode 55. Go back and listen to that one first if you have time! I think this is an important issue and it's one I'd like to highlight. Let me know what you think @ebrheum and please share with friends!
E63: Housekeeping #3
The podcast is back! I tune in briefly here to explain where I've been, what I'm doing, and where this will be headed. Feel free to skip right ahead if you'd rather just dig back in!
E57: PEXIVAS Trial - PLEX and Reduced Steroid in ANCA Vasculitis
PEXIVAS has landed! This week I go over the trial and my take on it's results. Impressive undertaking that answered two questions for a subset of patients with AAV - well worth the time to kick back and read the trial in full. Let me know what you think about the podcast @ebrheum!
E56: Continue or Withdraw Prednisone in SLE (CORTICOLUP)
(Yet) another RCT this week! Nice investigator initiated trial with many wonderful strengths and a few crippling flaws. Great opportunity to think about a common problem in practice as well as a separate common problem in trials!
E55: Anifrolumab for SLE (TULIP 1&2)
This week I talk about the recently published TULIP 1 and TULIP 2 trials that assessed anifrolumab for active SLE. Great to see a new drug in this disease state; interesting to think through how these trials played out. Get the papers and the pod at ebrheum.com and follow me @ebrheum if you'd like to share feedback!
E54: Rheum4Debate - Triple Tx is 1st Line in RA w/No Response to MTX
Happy New Year! This week Dr. Anisha Dua (@anisha_dua) and Dr. Sarah Fantus (@sarahfantus) debate this motion: "In MTX non-responders with RA, triple therapy (adding HCQ & SSZ) should be first line." Please be sure to VOTE AGAIN on twitter (@ebrheum) after you have listened!
E53: Another Look at Nintedanib for SSc-ILD
This week I go back to a topic from episode 42, the SENSCIS trial and nintedanib for SSc-ILD. The way this medication has been received and a recent article I wrote for The Rheumatologist gave me a nice jumping off point to cover a few more issues from this. Be sure to follow me @EBRheum to let me know what you think! The corresponding article is available here: https://www.the-rheumatologist.org
